

Ontuxizumab

Cat. No.:	HY-P99778
CAS No.:	946415-62-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer ^[1] .								
In Vitro	Ontuxizumab (0-100 μg/mL; 12 h) induces CD248 internalization and dose-dependently reduces 46% CD248 of cell surface of human pericytes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Human CD248 knock-in mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days</td> </tr> <tr> <td>Result:</td> <td>Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.</td> </tr> </table>	Animal Model:	Human CD248 knock-in mice ^[1]	Dosage:	50 mg/kg	Administration:	Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days	Result:	Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
Animal Model:	Human CD248 knock-in mice ^[1]								
Dosage:	50 mg/kg								
Administration:	Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days								
Result:	Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.								

REFERENCES

[1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. *Oncotarget*. 2015 Sep 22;6(28):25429-40.

[2]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. *Oncotarget*. 2015 Sep 22;6(28):25429-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA